Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
Spain
In shortPharma Mar, S.a. is profitable, generates cash and carries moderate debt, with revenue growing (+26.6% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 27.4% | 100/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 33.9% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 32.6% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 16.5% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.02× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.15× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 0.30× | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 9.33× | 75/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 7.96 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 21.1% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.62× | 40/100 |
| Years with positive free cash flow (last 5) | 3 of 5 | 50/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 20.0% | 37/100 |
| Operating margin volatility | 17.5% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 4.1% | 39/100 |
|---|---|---|
| EPS growth, 3-year average | 16.4% | 100/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.
Annual figures as reported. Hover a bar or point for the exact value.
1 older year available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
EUR millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 230 | 196 | 158 | 175 | 221 |
| Cost of revenue | 16 | 14 | 9.6 | 8.2 | 12 |
| Gross profit | 213 | 183 | 149 | 167 | 209 |
| Research & development | 72 | 83 | 99 | 104 | 95 |
| Operating income | 92 | 44 | (3.8) | 6.5 | 61 |
| Interest expense | 7.7 | 11 | 9.4 | 8.5 | 6.5 |
| Pre-tax income | 95 | 44 | (3.6) | 12 | 60 |
| Income tax | 2.3 | (5.6) | (4.8) | (14) | (15) |
| Net income | 93 | 49 | 1.1 | 26 | 75 |
| Diluted EPS | €5.13 | €2.73 | €0.06 | €1.49 | €4.30 |
1 older year available with the 10-year history. Essential plan, from €8.25/month →
7.96 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice.
Latest annual report: Dec 31, 2025 · Data updated Feb 27, 2026